Clinical trials: Personalized Medicine
Metastatic Colorectal Cancer
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
This randomized, phase 2 study will investigate the use of the Signatera ctDNA assay versus the standard scan-based approach to guide treatment in patients with metastatic colorectal cancer.
- Trial name
- NCT04786600
- Testing
- Signatera ctDNA assay, pre-specified sequence of FDA-approved drugs and drug combinations
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Florida
Tobacco Use Cessation
PRecision Interventions for SMoking in the SCCS
Precision Care (PC) interventions, developed with guidance from a Community Advisory Board (CAB), will be piloted in a Randomized Clinical Trial (RCT) of approximately 100 eligible, consenting daily smokers in the Southern…
- Trial name
- PRISM-SCCS (NCT03521141)
- Testing
- Nicotine patch, Varenicline, Nicotine metabolism
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Vanderbilt University Medical Center
Hypertension, Medication Adherence
Mi Propio Camino Intervention RCT for Blood Pressure Medication Adherence
The purpose of this study is to compare the effect of two educational interventions on adherence to blood pressure medications among adults with uncontrolled hypertension.
- Trial name
- MPC (NCT04585594)
- Testing
- Mi Propio Camino (MPC), Habilidades para Controlar la Presion (HCP; Skills for Blood Pressure Control)
- Where
- United States
- Volunteers
- 511 people
- Sponsor
- University of California, Irvine
Cocaine Use Disorder
Neurocognitive Factors in Substance Use Treatment Response: The Ways of Rewarding Abstinence Project
The proposed work will investigate changes in brain signaling and cognitive functioning that support recovery from addiction, as well as use of pretreatment neurocognitive functioning to inform substance use treatment planning.
- Trial name
- WRAP (NCT03799341)
- Testing
- Prize-Based Contingency Management, Treatment As Usual Outpatient Substance Use Treatment
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- VA Office of Research and Development
Heart Failure
Veterans Intensive Personalized Treatment in Heart Failure
In the VIP (Veterans Intensive Personalized) Treatment in Heart Failure Study we will assess 2 novel interventions to enhance adherence and improve quality of life in veterans with heart failure.
- Trial name
- VIP (NCT01404988)
- Testing
- Telephone-Delivered BI, Telephone-Delivered BEI, Telephone-Delivered API
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- US Department of Veterans Affairs
Feedback, Psychological, Clinical Trial
Personalized Health Assessment Related to Medications (Project PHARM)
This research will adapt an evidence based intervention for alcohol and other drugs and evaluate its efficacy on Prescription Stimulant Medication (PSM) misuse in a web-based format for use with college students who have misused…
- Conditions
- Feedback, Psychological, Clinical Trial, Substance Abuse
- Trial name
- NCT03037476
- Testing
- Web-based PFI, Assessment Only
- Where
- United States
- Volunteers
- 843 people, healthy volunteers welcome
- Sponsor
- University of Washington
Sports Medicine Injuries
Effect of Personalized Pain Coaches After Orthopaedic Surgery for Patients With Sports Medicine Injuries
Patients experiencing sports medicine-related injuries are particularly vulnerable to developing both chronic pain and experiencing prolonged opioid use.
- Trial name
- NCT05821699
- Testing
- LCS (Life Care Specialist), Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 148 people
- Sponsor
- Emory University
Healthy Adults, Genetic Predisposition to Disease
Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force
The MilSeq Project is a nonrandomized, prospective pilot study of whole exome sequencing (WES) in the U.S. Air Force. The purpose of this study is to explore the implementation of WES into clinical medical care in the military…
- Trial name
- MilSeq (NCT03276637)
- Testing
- Whole exome sequencing
- Where
- 3 sites in United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Blood Clotting
Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy
Warfarin is the most commonly used oral anticoagulant medicine (blood thinner). Although this medicine works well, it is difficult to know how much medicine a patient needs.
- Trial name
- PerMIT (NCT00993200)
- Testing
- warfarin pharmacogenetic dosing, Warfarin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Robert Pendleton
Pancreatic Adenocarcinoma
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
In this clinical trial, if the doctor knows or suspects that a growth in the pancreas is cancer (adenocarcinoma), then a sample of the growth is tested (the test is called molecular profiling).
- Trial name
- NCT01726582
- Testing
- Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery
- Where
- 2 sites in United States
- Volunteers
- 229 people
- Sponsor
- Medical College of Wisconsin
Treatment Resistant Depression, Refractory Depression
Ketamine for Older Adults Pilot
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD).
- Conditions
- Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression
- Trial name
- NCT04504175
- Testing
- Ketamine
- Where
- 5 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Non Small Cell Lung Cancer, BRCA1 Mutation
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
Primary objective: · Progression free survival. Secondary objectives: Assess Overall survival of both treatment groups. Assess Tumor response rate using RECIST criteria Assess Toxicity profile of patients enrolled in the study.
- Trial name
- BREC (NCT00617656)
- Testing
- Cisplatin, Docetaxel, Gemcitabine, Cisplatin, Docetaxel, Cisplatin
- Where
- 44 sites in Spain
- Volunteers
- 382 people
- Sponsor
- Spanish Lung Cancer Group
Alcoholism, Alcohol Use Disorder (AUD)
A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers
The purpose of this study is to advance the effort to develop personalized pharmacotherapy for alcohol use disorders (AUDs). The investigators propose to conduct a 12-week, prospective, randomized clinical trial of the moderating…
- Trial name
- TOPG (NCT02371889)
- Testing
- Topiramate, Medical Management
- Where
- 2 sites in United States
- Volunteers
- 320 people
- Sponsor
- University of Pennsylvania
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
This phase II MATCH treatment trial tests how well crizotinib works in treating patients with solid tumors, lymphoma, or multiple myeloma that may have spread from where it first started to nearby tissue, lymph nodes, or distant…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06357975
- Testing
- Biopsy Procedure, Biospecimen Collection, Crizotinib
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase IIa trial studies the side effects and how well TGR-1202 and ibrutinib work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement or does not respond to treatment.
- Trial name
- NCT02874404
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Genetic Diseases, Genetic Syndrome
Perinatal Precision Medicine
This study will seek to determine if rapid genomic sequencing improves outcomes for acutely ill infants. The investigator will enroll up to 1,000 acutely ill infants in a prospective, randomized, blinded study to either rapid…
- Conditions
- Genetic Diseases, Genetic Syndrome, Mendelian Disorders
- Trial name
- NSIGHT2 (NCT03211039)
- Testing
- Genomic sequencing and molecular diagnostic results, if any.
- Where
- United States
- Volunteers
- 213 people
- Sponsor
- Rady Pediatric Genomics & Systems Medicine Institute
Autism Spectrum Disorder
Translating Neuroprediction Into Precision Medicine Via Brain Priming
The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with Autism Spectrum Disorder (ASD).
- Trial name
- NCT03370510
- Testing
- Oxytocin, Pivotal Response Treatment
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Yale University
Liver Transplant, Kidney Transplant
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver and/or kidney transplant recipients to show improvement in maintaining drug trough levels within the target range.
- Trial name
- PPM - Pro (NCT03527238)
- Testing
- PPM-based Computation Assisted Drug Dosing, Tacrolimus
- Where
- 3 sites in United States, Singapore
- Volunteers
- 62 people
- Sponsor
- University of Florida